RMD Filing
4Filing Date: Jun 9, 2026
RESMED INC (RMD) · Insider Trading (Form 4) SEC Filing
Statement of Changes in Beneficial Ownership
descriptionView SEC Filing
ACC: 0000943819-26-000035open_in_new
Total Value$1.70M
Trades4
Insiders1
Transaction Details
Farrell Michael J.
Chairman and CEO, Director·Direct
Sell · Dispose
ResMed Common Stock
Shares-4.99K
Price$193.96
Total Value$968.1K
Shares Owned After466.26K
Transaction DateJun 8, 2026
10b5-1
Footnotes ▸
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. | This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price. | Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan.
Farrell Michael J.
Chairman and CEO, Director·Direct
Exercise · Acquire
ResMed Common Stock
Shares+4.99K
Price$146.34
Total Value$730.4K
Shares Owned After471.21K
Transaction DateJun 8, 2026
10b5-1
Footnotes ▸
The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
Farrell Michael J.
Chairman and CEO, Director·Direct
Exercise · Dispose
ResMed Common Stock OptionsDerivative
Shares-4.99K
Price$0.00
Total Value$0
Shares Owned After24.96K
Transaction DateJun 8, 2026
ExpiresNov 21, 2026
10b5-1
Farrell Michael J.
Chairman and CEO, Director·Indirect · Lisette and Michael Farrell Family Trust
ResMed Common Stock
Shares0
Price-
Total Value$0
Shares Owned After2.09K
10b5-1Holding Only
Post-Transaction Holdings
Farrell Michael J.
| Security | Shares | Change |
|---|---|---|
| ResMed Common Stock Options | 24.96K | -4.99K (-16.67%) |
| ResMed Common Stock | 468.35K | - |
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership ===
Document Type: 4
Period of Report: 2026-06-08
10b5-1 Pre-arranged Plan: Yes
--- Issuer ---
Name: RESMED INC (RMD)
CIK: 0000943819
--- Reporting Owner ---
Name: Farrell Michael J.
CIK: 0001485164
Role: Director, Officer (Chairman and CEO)
--- Non-Derivative Transactions ---
[Transaction #1]
Security: ResMed Common Stock
Date: 2026-06-08 | Code: M (Exercise of derivative)
Shares: +4,991 | Price: $146.34
Total Value: $730,382.94
Shares Owned After: 471,214 | Ownership: D (Direct)
Footnotes:
[F1] The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
[Transaction #2]
Security: ResMed Common Stock
Date: 2026-06-08 | Code: S (Open market sale)
Shares: -4,991 | Price: $193.96
Total Value: $968,064.34
Shares Owned After: 466,256 | Ownership: D (Direct)
Footnotes:
[F1] The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
[F2] This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price.
[F3] Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan.
--- Derivative Transactions ---
[Transaction #1]
Security: ResMed Common Stock Options
Date: 2026-06-08 | Code: M (Exercise of derivative)
Shares: -4,991 | Price: $0.00
Exercisable: N/A | Expires: 2026-11-21
Shares Owned After: 24,957 | Ownership: D (Direct)
--- Holdings ---
[Holding #1]
Security: ResMed Common Stock
Ownership: I (Indirect)
--- Footnotes (Complete Index) ---
F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2: This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price.
F3: Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan.
--- Signature ---
/s/ /s/ Michael J. Farrell, Chairman and CEO (2026-06-09)